BMY vs. CRL: Bristol-Myers Squibb vs. Charles River Laboratories Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Charles River Laboratories (CRL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while CRL is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Bristol-Myers Squibb (BMY) is defensive at 0.19 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Bristol-Myers Squibb (BMY) at 44.01% sits in the top ROE quartile, while Charles River Laboratories (CRL) at 1.27% is closer to the peer norm — stronger capital efficiency for BMY.

Bristol-Myers Squibb (BMY) at 18.47% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

Both Bristol-Myers Squibb (BMY) at 33.79% and Charles River Laboratories (CRL) at 23.42% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Bristol-Myers Squibb (BMY) at -0.22% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Bristol-Myers Squibb (BMY) at 1.59 and Charles River Laboratories (CRL) at 1.41 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but BMY is more stretched: Charles River Laboratories (CRL) at 0.87 sits in the higher-leverage quartile and Bristol-Myers Squibb (BMY) at 1.91 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Charles River Laboratories (CRL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

Charles River Laboratories (CRL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bristol-Myers Squibb (BMY) at 13.78 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Charles River Laboratories (CRL) at 4.07 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Bristol-Myers Squibb (BMY) at 5.43 and Charles River Laboratories (CRL) at 5.01 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics